ClinicalTrials.gg
RecruitingNCT06195306Updated Nov 19, 2026

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

A Phase 2 interventional study of Biospecimen Collection and Mammography in Breast Atypical Hyperplasia, Breast Carcinoma and Breast Ductal Carcinoma In Situ, sponsored by National Cancer Institute (NCI). Recruiting at 3 sites in United States. Open to female participants aged 45 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionCarcinoma, Intraductal, NoninfiltratingRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Intraductal, Noninfiltrating
Why
  1. The study's listed conditions name Carcinoma, Intraductal, Noninfiltrating, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
45 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating — 4 open to participants now, 6 under way, 3 of them phase 3. Tamoxifen · Carcinoma, Intraductal, Noninfiltrating.

Planned enrollment
13th of 15
66 · median 262
Started
2025
with 1 other
Phase 2
7 of 16
3 open now
Registered
15th of 16
by date
Lead sponsor
3 of 16
National Cancer Institute (NCI)

Among the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 2, and was the 15th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

4 of the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tamoxifen

Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 45 Years to 74 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, or all of them as a file.
02

Study summary

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. Omega-3 fatty acids may work to prevent cancer in overweight or obese individuals. Tamoxifen with or without omega-3 fatty acids may be effective at reducing risk of breast cancer among women who are postmenopausal, overweight or obese, and at increased risk.

Read the detailed description

PRIMARY OBJECTIVES:

I. To investigate average change in serum adiponectin within the low dose tamoxifen (LDTAM) + high dose omega-3-acid ethyl esters (omega-3 fatty acids) arm.

II. To study the beneficial effects of addition of high dose omega-3 fatty acids to LDTAM by comparing the relative difference in change in serum adiponectin in overweight and obese high-risk postmenopausal women randomized to 6 months of LDTAM or LDTAM + high dose omega-3 fatty acids.

SECONDARY OBJECTIVES:

I. To determine effect of LDTAM +/- high dose omega-3 fatty acids on insulin resistance, insulin sensitivity, and insulin secretory function (homeostatic model assessment for insulin resistance [HOMA-IR], homeostatic model assessment of insulin sensitivity [HOMA%S] homeostatic model assessment of beta cell function, [HOMA%B]), respectively.

II. To determine effect of LDTAM +/- high dose omega-3 fatty acid on benign breast tissue estrogen response gene index (ERGI).

EXPLANATORY OBJECTIVES:

I. Effect of change in red blood cell (RBC) omega-3:omega-6 fatty acid ratio on within arm change in blood adiponectin.

II. Effect of change in RBC omega-3:omega-6 fatty acid ratio on within arm change in tissue ERGI.

III. Effect of baseline bioavailable estradiol on within arm change in blood adiponectin.

IV. Effect of baseline and 6-month bioavailable estradiol on within arm change in tissue ERGI.

V. Effect of 6-month tamoxifen active metabolites (endoxifen and 4-hydroxy [4OH] tamoxifen) on change in ERGI.

VI. Effect of eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) dietary intake as measured by DHA Food Frequency Questionnaire on RBC omega 3:6 fatty acid ratio change.

EXPLORATORY OBJECTIVES:

I. Assess within arm effects of LDTAM +/- high dose omega-3 fatty acids on serum triglycerides.

II. Assess within arm effects of LDTAM +/- high dose omega-3 fatty acids on adiponectin:leptin ratio.

III. Assess within arm effects of LDTAM +/- high dose omega-3 fatty acids on anterior gradient protein 2 homolog (AGR2) messenger ribonucleic acid (mRNA).

IV. Assess within effects of LDTAM +/- high dose omega-3 fatty acids on forkhead box A1 (FOXA1) protein (immunohistochemistry [IHC]).

V. Assess within arm effects of LDTAM +/- high dose omega-3 fatty acids on AGR2 protein (IHC).

VI. Assess effects of LDTAM +/- high dose omega-3 fatty acids on Ki-67 (IHC) in individuals with > 500 cells in baseline ThinPrep and measurable baseline Ki-67.

OUTLINE: Participants are randomized to 1 of 2 groups.

GROUP 1: Participants receive tamoxifen by mouth (PO) once daily (QD) for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo random periareolar fine needle aspiration (RPFNA) and collection of blood samples at screening and on study.

GROUP 2: Participants receive tamoxifen PO QD and omega-3 fatty acids PO twice daily (BID) for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD and omega-3 fatty acids PO BID for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.

After completion of study intervention, participants are followed up at 21-35 days.

03

Conditions studied

  • Breast Atypical Hyperplasia
  • Breast Carcinoma
  • Breast Ductal Carcinoma In Situ
  • Breast Lobular Carcinoma In Situ
04

In context

Carcinoma, Intraductal, Noninfiltrating Reclassified

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

This study's planned enrollment of 66 is close to the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Carcinoma, Intraductal, Noninfiltrating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Age 45 - 74
  • female

    • Postmenopausal is defined as either

      • Prior removal of the ovaries, or if ovaries intact amenorrhea for >= 12 months and not on any form of , or
      • Amenorrhea for greater than 2 months with serum follicle-stimulating hormone (FSH) in postmenopausal range (>= 25 IU/L). Women with ovaries and a prior hysterectomy or endometrial ablation \< age 55 must have a FSH >= 25 IU/L. Women may be on vaginal low dose estrogen preparations for vaginal dryness. Women over age 50 with a levonorgestrel intrauterine device in place for 2 or more years and not planning removal in the next 6 month are also eligible if FSH >= 25 IU/L

        • Note: FSH will be done at time of screening
  • Women with intact ovaries and uterus \< age 55 must have a negative pregnancy test prior to randomization
  • Overweight or obese ( [BMI] >= 25 kg/m\^2)

    • Note: BMI must be calculated within 28 days of randomization
  • Willing to undergo a fasting blood draw and non-fasting RPFNA with fixed and frozen aliquots sent to University of Kansas Medical Center (KUMC)
  • At increased risk of breast cancer per at least one of the following:

    • Personal medical history

      • History of atypical hyperplasia or lobular carcinoma in situ (LCIS) found on breast
      • History of unilateral ductal carcinoma in situ treated with unilateral mastectomy, lumpectomy, or local excision with or without radiation and this treatment was completed at least 3 months prior to the screening RPFNA
      • High mammographic density determined by one of the following:

        • Visual estimate of area of density (VAS) > 50%,
        • Volpara (trademark) >= 15% dense volume (Volpara d)
        • Breast Imaging Reporting and Data System (BIRADS) assessment = extremely dense (BIRADs D)
    • Genetic test result

      • Germline gene mutation in ATM, BARD1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, or STK11
      • Polygenic lifetime risk score >= 2x average or 25%
    • Calculated risk based on standard models

      • Five-year Breast Cancer Risk Assessment Tool (BCRAT) (version 2.0) >= 1.66%
      • Ten-year International Breast Cancer Intervention Study risk evaluation tool (IBIS) (version 8) >= 3%
      • Ten-year relative risk IBIS (version 8) >= 2X that for age group
      • Ten- year Breast Cancer Surveillance Consortium (version 2) >= 3%
    • Family History

      • Breast cancer in a first or second degree relative (female or male) with onset under age 50. (First degree relative = parent, sibling, or child. Second degree relative = grandparent, uncle, aunt, nephew, niece, half-sibling, grandchild or first cousin)
      • Breast cancer in two or more first or second-degree relatives from either the maternal or paternal linage without regard to age
      • Bilateral breast cancer or breast and ovarian cancer in the same first or second degree relative without regard to age
    • Primary source documentation of risk is required and must be submitted to the lead academic organization (LAO) for review along with the eligibility checklist

      • Risk factor: Atypical hyperplasia or LCIS; Primary source document: Copy of pathology report or clinical note confirming the diagnosis
      • Risk factor: Ductal carcinoma in situ (DCIS) and treatment history; Primary source document: Copies of pathology report or clinic notes confirming the diagnosis, treatment plan and treatment end date(s)
      • Risk factor: Mammographic density; Primary source document: Copy of clinic note or mammogram report
      • Risk factor: Genetic; Primary source document: Copy of genetic test report
      • Risk factor: Calculated based on standard models; Primary source document: Copy of the calculation result
  • Total =\< 1.5 x institutional (ULN)

    • Note: Higher total bilirubin levels (=\< 3 mg/dL) can be allowed if due to known benign liver condition, i.e., Gilbert's syndrome
    • Results from prior laboratory testing within 180 days of randomization may be used
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =\< 3.0 x institutional upper limit of normal

    • Results from prior laboratory testing within 180 days of randomization may be used
  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 3.0 x institutional upper limit of normal

    • Results from prior laboratory testing within 180 days of randomization may be used
  • (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible
  • (ECOG) performance status =\< 2 ( >= 60%)
  • Women must have at least 1 unaffected untreated breast for fine needle aspiration. Women may have had prior unilateral breast radiation or mastectomy for DCIS
  • Ability to understand and the willingness to sign a written document
  • Most recent screening mammogram must be performed ≤ 12 months prior to RPFNA and must be reported as BIRAD 1 or 2. If BIRAD 0 then follow-up diagnostic imaging must be BIRAD 1 or 2 or cleared clinically with radiology recommendation of return to annual screening
  • Confirmation that baseline research blood was drawn fasting (>= 10 hours), has been received in good condition at KUMC, and is archived for assessment of primary endpoint

Exclusion Criteria:

  • Exclusions based on current or past conditions:

    • Bilateral breast implants (danger of implant puncture with RPFNA)
    • Prior invasive breast cancer
    • Prior invasive uterine cancer
    • Other prior invasive cancer and haven't completed cancer related therapy or with evidence of disease (other than non-melanoma skin cancer) within the past 2 years
    • Currently breastfeeding (concern that tamoxifen may be in breast milk) or nursing within past 12 months (concern about milk fistula with RPFNA)
    • Type I or type II diabetes mellitus requiring current pharmacologic treatment (including metformin, glucagon-like peptide 1 agonists, insulin, sulfonylurea)
    • Prior deep vein thrombosis, pulmonary embolus, or stroke
    • Prior gastric bypass surgery
    • History of chronic liver disease including NASH (nonalcoholic steatohepatitis) or cirrhosis
    • Pathogenic or likely pathogenic germline mutation in BRCA1 or TP53
  • Exclusions based on medications:

    • Current use of prescription anticoagulants such as Coumadin (warfarin), direct-acting oral anticoagulants such as Xarelto (rivaroxaban) or Eliquis (apixaban) or heparin
    • Women who would not be able to or do not wish to discontinue daily use of aspirin (81mg or higher) and aspirin containing products (81 mg or higher) at least 3 weeks prior to each RPFNA

      • Note: Women may resume daily use of aspirin and aspirin containing products 3 days after each RPFNA procedure
    • Current use of a levonorgestrel intrauterine device if in place less than 2 years or if there is planned removal within the next 6 months
    • Current use of hormone therapy (oral, transdermal, or injectable)

      • Note: Vaginal estrogen is allowed
    • Prior treatment with tamoxifen, aromatase inhibitor or selective estrogen receptor degrader for more than 2 months

      • Note: Women with \< 2 months of these drugs must be off for at least 6 months before they may begin biomarker screening tests
    • Greater than 1 gram daily of omega-3 fatty acid supplement within the last 6 months
    • Current use of prescription drugs
    • Current use of strong inducers rifampin or aminoglutethimide
    • Current use of or plans to initiate a glucagon-like peptide 1 agonist within the next 6 months
    • Current use of metformin for any indication
  • Participants may not be receiving any other agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen or omega-3 fatty acid or generic Lovaza or compounds of similar chemical composition
  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Group 1 (tamoxifen)

    Participants receive tamoxifen PO QD for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.

    Procedure: Biospecimen Collection · Procedure: Mammography · Other: Questionnaire Administration · Procedure: Random Periareolar Fine-Needle Aspiration · Drug: Tamoxifen

  • Experimental
    Group 2 (tamoxifen, omega-3 fatty acids)

    Participants receive tamoxifen PO QD and omega-3 fatty acids PO BID for 180 days in the absence of unacceptable toxicity. Participants may continue to receive tamoxifen PO QD and omega-3 fatty acids PO BID for up to 60 additional days in the case of scheduling delays. Participants also undergo mammography at screening and undergo RPFNA and collection of blood samples at screening and on study.

    Procedure: Biospecimen Collection · Procedure: Mammography · Drug: Omega-3-Acid Ethyl Esters · Other: Questionnaire Administration · Procedure: Random Periareolar Fine-Needle Aspiration · Drug: Tamoxifen

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureMammography

    Undergo mammography

    Also known as: MG

  • DrugOmacorStudies of OmacorOmacor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: Lovaza

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureRandom Periareolar Fine-Needle Aspiration

    Undergo RPFNA

    Also known as: Random Periareolar Fine Needle Aspiration, RPFNA

  • Given PO

    Also known as: TMX

07

What researchers measure

Primary outcomes

  1. Change in serum adiponectin

    An analysis for difference between the two arms will be conducted to document a beneficial effect of addition of high dose omega-3 fatty acids to low dose tamoxifen. Paired and unpaired t-tests will be used.

    Time frame: From baseline up to end of treatment (6 months)

Secondary outcomes

  1. Change in insulin resistance

    Evaluated using Homeostatic Model Assessment of Insulin Resistance, as calculated using fasting glucose and fasting insulin. Paired and unpaired t-tests will be used. Spearman correlation between change in biomarkers will be estimated and compared across the study arms using Fisher's Z-transformed values.

    Time frame: From baseline up to end of treatment (6 months)

  2. Change in insulin sensitivity

    Evaluated using Homeostatic Model Assessment of Insulin Sensitivity. Paired and unpaired t-tests will be used. Spearman correlation between change in biomarkers will be estimated and compared across the study arms using Fisher's Z-transformed values.

    Time frame: From baseline up to end of treatment (6 months)

  3. Change in insulin secretory function

    Evaluated using Homeostatic Model Assessment of Beta Cell Function. Paired and unpaired t-tests will be used. Spearman correlation between change in biomarkers will be estimated and compared across the study arms using Fisher's Z-transformed values.

    Time frame: From baseline up to end of treatment (6 months)

  4. Estrogen response gene index (ERGI)

    The estrogen response gene index reflects change in gene expression over time. The genes assayed for this index are: ESR1 (codes for estrogen receptor alpha), ESR2 (codes for estrogen receptor beta), GREB1 (codes for growth regulation by estrogen in breast cancer 1), PGR (codes for progesterone receptor) and TFF1 (also known as pS2, which codes for trefoil factor 1). The log2-transformed values of the ratio of relative abundance (6-month value: baseline value) for GREB1, PGR, TFF1, and the ratio of ESR1:ESR2 are averaged to produce the ERGI. Paired and unpaired t-tests will be used. Spearman correlation between change in biomarkers will be estimated and compared across the study arms using Fisher's Z-transformed values.

    Time frame: From baseline up to end of treatment (6 months)

Other outcomes

  1. Effect of change in red blood cell omega-3:omega-6 fatty acid ratio on within arm change in blood adiponectin

    Assess correlation between change in red blood cell omega-3:omega-6 fatty acid ratio and change in blood adiponectin levels.

    Time frame: From baseline to end of treatment (6 months)

  2. Effect of change in red blood cell omega-3:omega-6 fatty acid ratio on within arm change in tissue ERGI

    Assess correlation between change in red blood cell omega-3:omega-6 fatty acid ratio on within arm change in tissue ERGI.

    Time frame: From baseline to end of treatment (6 months)

  3. Effect of baseline bioavailable estradiol on within arm change in blood adiponectin

    Assess correlation between baseline bioavailable estradiol on within arm change in blood adiponectin.

    Time frame: From baseline to end of treatment (6 months)

  4. Effect of baseline and 6-month bioavailable estradiol on within arm change in tissue ERGI

    Assess correlation between baseline and 6-month bioavailable estradiol on within arm change in tissue ERGI.

    Time frame: From baseline to end of treatment (6 months)

  5. Effect of 6-month tamoxifen active metabolites on change in ERGI

    Assess correlation between 6-month tamoxifen active metabolites on change in ERGI.

    Time frame: From baseline to end of treatment (6 months)

  6. Effect of eicosapentaenoic acid/docosahexaenoic acid dietary intake on red blood cell omega-3:omega-6 fatty acid ratio change

    Effect of eicosapentaenoic acid/docosahexaenoic acid dietary uptake during intervention on change in red blood cell omega-3:omega-6 fatty acid ratio.

    Time frame: From baseline to end of treatment (6 months)

  7. Serum triglycerides

    Will evaluate within arm effects of low dose tamoxifen +/- high dose omega-3 fatty acids on this exploratory outcome.

    Time frame: Up to 6 months

  8. Adiponectin:leptin ratio

    Will evaluate within arm effects of low dose tamoxifen +/- high dose omega-3 fatty acids on this exploratory outcome.

    Time frame: Up to 6 months

  9. Anterior gradient protein 2 homolog messenger ribonucleic acid

    Will evaluate within arm effects of low dose tamoxifen +/- high dose omega-3 fatty acids on this exploratory outcome.

    Time frame: Up to 6 months

  10. Forkhead box A1 protein

    Will evaluate within arm effects of low dose tamoxifen +/- high dose omega-3 fatty acids on this exploratory outcome.

    Time frame: Up to 6 months

  11. Anterior gradient protein 2 homolog protein

    Will evaluate within arm effects of low dose tamoxifen +/- high dose omega-3 fatty acids on this exploratory outcome.

    Time frame: Up to 6 months

  12. Ki-67

    Will evaluate within arm effects of low dose tamoxifen +/- high dose omega-3 fatty acids on this exploratory outcome.

    Time frame: Up to 6 months

08

Study locations

3 of 3 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 36 phase 2 interventional studies under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 170. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 8, 2024
StartActual
Jul 28, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06195306
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Jul 28, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Lauren Nye
principal investigator · University of Kansas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion